scispace - formally typeset
L

Luisa Aran

Researcher at University of Naples Federico II

Publications -  9
Citations -  2440

Luisa Aran is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Sarcopenia & Blood pressure. The author has an hindex of 7, co-authored 9 publications receiving 1346 citations.

Papers
More filters
Journal ArticleDOI

Oxidative stress, aging, and diseases.

TL;DR: Given the important role of oxidative stress in the pathogenesis of many clinical conditions and aging, antioxidant therapy could positively affect the natural history of several diseases, but further investigation is needed to evaluate the real efficacy of these therapeutic interventions.
Journal ArticleDOI

Sarcopenia: assessment of disease burden and strategies to improve outcomes.

TL;DR: Because sarcopenia is associated with important adverse health outcomes, such as frailty, hospitalization, and mortality, several therapeutic strategies have been identified that involve exercise training, nutritional supplementation, hormonal therapies, and novel strategies and are still under investigation.
Journal ArticleDOI

Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients.

TL;DR: The authors describe the mechanisms of cardiotoxicity induced by anthracyclines, which can lead to cardiovascular problems in up to 48% of patients who take them, and outline the recent advances in immunotherapies, which have revolutionised anticancer therapies.
Journal ArticleDOI

Orthostatic Hypotension in the Elderly: A Marker of Clinical Frailty?

TL;DR: OH is a common condition in frail older adults, and it is strongly associated with mortality, disability, and hospitalization in the highest frailty degree, and may represent a new marker of clinical frailty.
Journal ArticleDOI

Impact of SPRINT results on hypertension guidelines: implications for "frail" elderly patients.

TL;DR: It has been described that light frailty is related to good outcomes in older adults and frailty status should be routinely and correctly quantified in order to identify the frailty degree and to find the best harms–benefits balance of antihypertensive drug treatment in frail older adults.